BALATON and COMINO: Phase III Randomized Clinical Trials of Faricimab for Retinal Vein Occlusion

BALATON and COMINO: Phase III Randomized Clinical Trials of Faricimab for Retinal Vein Occlusion

Purpose: Dual inhibition of angiopoietin-2 and VEGF-A with faricimab (Vabysmo) offers excellent visual acuity gains with strong durability in patients with diabetic macular edema (ME) and neovascular age-related macular degeneration. The phase III BALATON/COMINO (NCT04740905/NCT04740931) trials will...

Full description

Bibliographic Details
Main Authors: Lars-Olof Hattenbach, MD, PhD, Francis Abreu, PhD, Pablo Arrisi, PhD, Karen Basu, PhD, Carl J. Danzig, MD, Robyn Guymer, MD, PhD, Zdenka Haskova, MD, PhD, Jeffrey S. Heier, MD, Aachal Kotecha, PhD, Ying Liu, PhD, Anat Loewenstein, MD, András Seres, MD, Jeffrey R. Willis, MD, PhD, Charles C. Wykoff, MD, PhD, Liliana P. Paris, MD, PhD
Format: Article
Language:English
Published: Elsevier 2023-09-01
Series:Ophthalmology Science
Subjects:
Angiopoietin-2
Faricimab
Macular edema
Retinal vein occlusion
Vascular endothelial growth factor receptor
Online Access:http://www.sciencedirect.com/science/article/pii/S2666914523000349

Internet

http://www.sciencedirect.com/science/article/pii/S2666914523000349

Similar Items